PDE5A and Duchenne muscular dystrophy: Because of the importance of monitoring cardiac function in patients with DMD, and the potential for cardiac effects of PDE5 inhibition, this trial also collected serial echocardiograms, electrocardiograms, vital signs, and adverse events as safety measures from all randomized patients and performed cardiac magnetic resonance (CMR) imaging in a subset of patients.